Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD
Portfolio Pulse from Lara Goldstein
Numinus Wellness' Cedar Clinical Research has joined COMPASS Pathways' Phase 3 program studying psilocybin therapy for Treatment-Resistant Depression (TRD). The trial is part of the largest-ever international clinical program assessing psilocybin therapy, enrolling over 800 participants. Topline data from the Phase 3 clinical program is expected in summer 2024 and mid-2025.
May 30, 2023 | 8:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
COMPASS Pathways' Phase 3 program on psilocybin therapy for TRD is joined by Numinus Wellness' Cedar Clinical Research, potentially benefiting from the partnership.
Numinus Wellness' Cedar Clinical Research joining COMPASS Pathways' Phase 3 program on psilocybin therapy for TRD is a positive development for COMPASS. The partnership could lead to increased visibility and potential revenue streams for COMPASS Pathways, as well as contribute to the growing body of research in the field.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Numinus Wellness' Cedar Clinical Research joins COMPASS Pathways' Phase 3 program on psilocybin therapy for TRD, potentially benefiting from the partnership.
Numinus Wellness' Cedar Clinical Research joining COMPASS Pathways' Phase 3 program on psilocybin therapy for TRD is a positive development for the company. The partnership could lead to increased visibility and potential revenue streams for Numinus Wellness, as well as contribute to the growing body of research in the field.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80